Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 8/20 | 0.58 |
| ▸ | MTNR1B | P49286 | 8/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12877288 | 0.89 | MTNR1A (0.44) | MTNR1AMTNR1BHSD17B10SMN1; SMN2 | |
| SCHEMBL9186971 | 0.87 | MTNR1A (0.63) | MTNR1AMTNR1BTP53HSD17B10SMN1; SMN2 | |
| SCHEMBL14494995 | 0.86 | MTNR1A (0.58) | MTNR1AMTNR1BTP53HSD17B10 | |
| SCHEMBL14495036 | 0.83 | NQO2 (0.45) | MTNR1AMTNR1B | |
| SCHEMBL14494994 | 0.80 | MTNR1A (0.55) | MTNR1AMTNR1BTP53HSD17B10SMN1; SMN2 | |
| SCHEMBL1009815 | 0.79 | MTNR1A (0.75) | MTNR1AMTNR1BSMN1; SMN2 | |
| SCHEMBL9988696 | 0.79 | MTNR1A (0.54) | MTNR1AMTNR1BSMN1; SMN2 | |
| SCHEMBL14494987 | 0.79 | MTNR1A (0.63) | MTNR1AMTNR1BTP53HSD17B10SMN1; SMN2 | |
| SCHEMBL6555821 | 0.78 | MTNR1B (0.64) | MTNR1AMTNR1BTP53HSD17B10 | |
| SCHEMBL153172 | 0.78 | TAAR1 (0.54) | MTNR1AMTNR1BHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070142399-A1 | Dual function drugs and uses thereof | PSYCHIATRIC GENOMICS, INC. (US) | 2007-06-21 | — | — | US | disclosed |
| US-20070142399-A1 | Dual function drugs and uses thereof | PSYCHIATRIC GENOMICS, INC. (US) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142399-A1 | Dual function drugs and uses thereof | COMT, DRD2, SLC6A3 | MTNR1A 34/4885MTNR1B 25/4885TP53 1824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.